ArticleRheumatology international2026
Performance of inflammatory back pain criteria in axial psoriatic arthritis compared with non-psoriatic axial spondyloarthritis and chronic low back pain: a cross-sectional study.
Article in Rheumatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
46 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To compare the within-study discriminatory characteristics of established inflammatory back pain (IBP) criteria sets and individual items in predefined groups of patients with axial psoriatic arthritis (axPsA), non-psoriatic axial spondyloarthritis (axSpA), and chronic mechanical low back pain (cLBP). Data were drawn retrospectively from a multicentre PsA registry and a separate single-center axSpA/cLBP cohort. IBP criterion sets (Calin, ASAS, Berlin) and individual IBP items were evaluated using sensitivity, specificity, likelihood ratios, and area under the receiver operating characteristic curve (AUC). Because case and comparator groups were predefined rather than prospectively assembled from an unselected diagnostic population, the estimates represent classification-discrimination within the study sample, not real-world diagnostic accuracy. A total of 697 patients were analyzed, including 282 patients with axPsA, 292 with axSpA, and 123 with cLBP. In these selected comparisons, Calin and ASAS criteria showed high observed specificity, whereas Berlin criteria showed greater sensitivity (91.1% in axPsA and 86.7% in axSpA). Among individual IBP items, insidious onset showed the highest AUC in both comparisons (0.939, 95% CI 0.911-0.961 in axPsA and 0.913, 95% CI 0.881-0.939 in axSpA). In contrast, age at onset < 40 years and good response to NSAIDs showed little discrimination in axPsA (AUC 0.544 and 0.543, respectively). In multivariable analyses, Calin, ASAS, and Berlin criteria were associated with axPsA group membership, while Calin and ASAS criteria showed the strongest associations with axSpA group membership; conventional and Firth models yielded directionally similar estimates. Within these predefined cohorts, IBP criteria and individual items differed in their ability to discriminate group membership. IBP should be regarded as a supportive clinical feature, not a standalone screening or diagnostic tool. The high specificity and positive likelihood ratio estimates may reflect enrichment of symptom- and imaging-positive cases and use of an ASAS-negative cLBP comparator; prospective validation in unselected clinical populations is required.
Indexed as
Identifiers
42821151What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.